EQS-News: MEDIQON Group AG
/ Key word(s): Personnel
MEDIQON Group AG: Executive Board contract of Jan-Hendrik Mohr extended
Yesterday, the company's Supervisory Board unanimously extended the contract of CEO Jan-Hendrik Mohr until December 31, 2027. Supervisory Board Chairman Dr. Mathias Saggau commented: "We are happy that Jan wants to continue to drive the growth of MEDIQON Group AG and committed to lead the next chapter of our development. This ensures continuity in the management of the Group for a long time to come." Jan-Hendrik Mohr: "I’m grateful for the great trust placed in me and I look forward to shape the future of MEDIQON Group AG in the next years as part of a great team!"
16.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | MEDIQON Group AG |
Herzog-Adolph-Strasse 2 | |
61462 Königstein im Taunus | |
Germany | |
Phone: | +49 (0) 6174-9687040 |
Fax: | +49 (0) 6174-9687043 |
E-mail: | ir@mediqon-group.de |
Internet: | www.mediqon-group.de |
ISIN: | DE0006618309, DE000A254TL0 |
WKN: | 661830, A254TL |
Listed: | Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart |
EQS News ID: | 1561633 |
End of News | EQS News Service |
|
1561633 16.02.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.